Assessment and characteristics of Erenumab therapy on migraine management

Saeed, Haitham; Tulbah, Alaa S.; Gamal, Amr; Kamal, Marwa

doi:10.1016/j.jsps.2022.06.015

Cited by 2 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 46 studies included participants of male or female sex [ 38 – 83 ]. Twenty-seven studies included participants with either EM or CM [ 38 , 40 – 46 , 48 , 54 – 56 , 60 , 61 , 65 , 69 – 71 , 73 – 76 , 78 , 80 – 83 ]. Nineteen studies only looked at participants with CM [ 39 , 47 , 49 – 53 , 57 – 59 , 62 – 64 , 66 – 68 , 72 , 77 , 79 ].…”

Section: Resultsmentioning

confidence: 99%

“…Studies had a median number of 111 participants (interquartile range 61 to 164 participants). Nineteen studies (41.3%) formulated exclusion criteria for participation in the study [ 46 , 49 , 50 , 52 – 56 , 60 , 61 , 63 – 67 , 69 , 72 , 73 , 83 ]. Twenty-five studies (54.3%) used a minimum age [ 40 , 41 , 43 , 45 , 46 , 49 , 50 , 53 , 54 , 56 , 58 – 60 , 62 , 64 , 66 , 67 , 70 , 72 – 74 , 79 – 81 , 83 ].…”

Section: Resultsmentioning

confidence: 99%

“…Eleven 11 studies (23.9%) used a maximum age in the inclusion and exclusion criteria [ 41 , 43 , 45 , 46 , 53 , 54 , 66 , 67 , 72 , 74 , 83 ]. The start date was not reported in 7 studies (15.2%) [ 39 , 51 , 57 , 69 , 73 , 77 , 78 ]. The end date was not reported in 6 studies (13%) [ 39 , 51 , 57 , 69 , 73 , 77 ].…”

Section: Resultsmentioning

confidence: 99%

“…The start date was not reported in 7 studies (15.2%) [ 39 , 51 , 57 , 69 , 73 , 77 , 78 ]. The end date was not reported in 6 studies (13%) [ 39 , 51 , 57 , 69 , 73 , 77 ].…”

Section: Resultsmentioning

confidence: 99%

“…The following drugs and subcutaneous dosing schemes were used: erenumab 70 mg monthly ( n = 23, 50%) [ 42 , 45 , 47 – 49 , 51 , 54 , 56 , 58 – 60 , 62 , 66 – 68 , 70 – 73 , 75 , 77 , 82 , 83 ], galcanezumab 240 mg loading dose followed by 120 mg monthly ( n = 21, 45.7%) [ 38 – 40 , 47 , 56 , 58 – 61 , 67 , 69 , 70 , 74 – 76 , 78 – 82 ], erenumab 140 mg monthly ( n = 20, 43.5%) [ 38 , 45 , 47 – 49 , 54 , 56 , 58 – 60 , 62 , 67 , 69 – 72 , 75 – 77 , 82 ], erenumab 140 mg every 4 weeks ( n = 11, 23.9%) [ 39 , 43 , 46 , 50 , 52 , 53 , 55 – 57 , 63 , 65 ], erenumab 70 mg every 4 weeks ( n = 11, 23.9) [ 39 , 41 , 43 , 46 , 52 , 53 , 55 – 57 , 64 ...…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

Vandenbussche,

Pisarek,

Paemeleire

2023

J Headache Pain

View full text Add to dashboard Cite

Background Real-world data are accumulating on the effectiveness, tolerability and safety of anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine. We performed a systematic review of the methodology of prospective, observational, clinic-based real-world evidence studies with these drugs in both episodic and chronic migraine. Methods The objectives were to evaluate the definitions and reported outcomes used, and to perform a risk of bias assessment for each of the different studies. PubMed and EMBASE were systematically queried for relevant scientific articles. Study quality assessment of the included studies was conducted using the “National Heart, Lung and Blood Institute (NHLBI) Study Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group”. Results Forty-six studies fitted the criteria for the systematic review and were included in the analysis. Ten studies (21.7%) defined a migraine day for the study, while only 5 studies defined a headache day for the study (10.9%). The most common primary endpoint/objective of the studies was change in monthly migraine days (n = 16, 34.8%), followed by responder rate (n = 15, 32.6%) and change in monthly headache days (n = 5, 10.9%). Eight studies (17.4%) did not define the primary endpoint/objective. Thirty-three studies were graded as “good” quality and 13 studies were graded as “fair”. Conclusion Our analysis shows rather significant heterogeneity and/or lack of predefined primary outcomes/objectives, definitions of outcomes measures and the use of longitudinal monitoring (e.g. headache diaries). Standardization of terminology, definitions and protocol procedures for real-world evidence studies of preventive treatments for migraine are recommended. Trial registration This study was registered with PROSPERO with ID CRD42022369366.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…The start date was not reported in 7 studies (15.2%) [ 39 , 51 , 57 , 69 , 73 , 77 , 78 ]. The end date was not reported in 6 studies (13%) [ 39 , 51 , 57 , 69 , 73 , 77 ].…”

Section: Resultsmentioning

confidence: 99%